Successful Drug Development Despite Adverse Preclinical Findings Part 2: Examples

To illustrate the process of addressing adverse preclinical findings (APFs) as outlined in the first part of this review, a number of cases with unexpected APF in toxicity studies with drug candidates is discussed in this second part. The emphasis is on risk characterization, especially regarding th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ettlin, Robert A., Kuroda, Junji, Plassmann, Stephanie, Hayashi, Makoto, Prentice, David E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Toxicologic Pathology 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234630/
https://www.ncbi.nlm.nih.gov/pubmed/22272032
http://dx.doi.org/10.1293/tox.23.213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234630/
https://www.ncbi.nlm.nih.gov/pubmed/22272032
http://dx.doi.org/10.1293/tox.23.213

Ejemplares similares